特朗普：将大幅降价！巨头股价暴跌

Group 1 - The core viewpoint is that President Trump announced a significant price reduction for diabetes and weight loss drugs, including Novo Nordisk's drug Ozempic, which has caused market volatility in the pharmaceutical sector [1][3]. - Trump stated that the out-of-pocket cost for patients using Ozempic will drop to $150 per month from the current price of approximately $1,000 per month [3]. - The Centers for Medicare & Medicaid Services clarified that negotiations regarding the drug prices are still ongoing and no agreement has been reached yet [3]. Group 2 - Following Trump's announcement, Novo Nordisk's stock price in Copenhagen fell by over 6.3%, while its main competitor, Zealand Pharma, saw a decline of over 8%, and Eli Lilly's stock in New York dropped by 2% [5]. - Ozempic, which contains the active ingredient semaglutide, has been approved in multiple countries for diabetes and weight loss treatment, with the global market for related drugs reaching hundreds of billions of dollars annually [5]. - Other pharmaceutical companies, such as Zealand Pharma and Eli Lilly, have also launched similar drugs in recent years [5].